SOLOTHURN, Switzerland ILLKIRCH-GRAFFENSTADEN, France – 10/10/2025
abc biopply ag, a Swiss biotech company specializing in humanized 3D disease models, and Inoviem Scientific, a French bioanalytical R&D company, have entered a strategic collaboration to develop and commercialize a new preclinical service for the pharmaceutical and biotech industries. This joint effort will create a highly predictive, patient-relevant drug testing platform by uniquely integrating Inoviem’s direct access to fresh patient tumor biopsies with abc biopply’s proprietary 3D multi-organoid technology™.
A Paradigm Shift in Preclinical Drug Evaluation
This collaboration marks a significant step forward in preclinical research by addressing the critical challenge of translational accuracy. The new models aim to bridge the gap between early-stage drug evaluation and clinical reality. By integrating fresh human tissue with physiologically relevant 3D models, the new platform will provide a powerful tool for early-stage drug evaluation, which can help reducing attrition and accelerate decision-making in oncology drug development. The new models will reach the market as CRO services and are designed to deliver clinically anchored efficacy data using patient-derived tumor material, provide mechanistic insights into drug resistance to support personalized oncology, and ultimately improve translational accuracy between preclinical assays and Phase II/III clinical trials
Leveraging Complementary Strengths for a Unified Solution
The partnership leverages the distinct yet complementary expertise of both companies. Inoviem Scientific contributes its proven bioanalytical and clinical study experience to the collaboration. Its key responsibilities include performing rapid sample processing and “Pharmacology on the Spot,” where initial pharmacological treatments are applied ex vivo to biopsy material within minutes of surgical removal. This innovative method minimizes cold ischemia effects and preserves the integrity of the tumor microenvironment. Inoviem is also responsible for patient biopsy procurement, initially focusing on triple-negative breast cancer (TNBC) biopsies, with the flexibility to expand to other indications. Additionally, the company ensures optimized sample shipment, maintaining the integrity and viability of fresh, unfrozen samples during transport to abc biopply.
abc biopply, on the other hand, brings its leading expertise in cell culture modelling and its proprietary 3D multi-organoid technology™ to the platform. Its CRO services center around developing and optimizing protocols for dissociating tumor tissue and adapting it to 3D organoid models preserving physiological microenvironments. The company will also analyse clonal growth from individual cells and provide insights into relative survival rates and drug efficacies on specific cell types and conduct identification and quantification of drug related resistances.
Dr. Arne-C. Faisst, CEO of abc biopply ag, stated, “This collaboration significantly expands abc biopply’s disease models and the related services giving us the ability to support our clients with preclinical predictiveness that is more personalized and precise than ever before.”
Pierre Eftekhari, President and CSO of Inoviem Scientific, added, “Inoviem has pioneered translational pharmacology, with a mission to get the right treatment to the right patient within the right therapeutic window. Our collaboration with abc biopply will enable us to close the loop between the clinic and the lab, providing invaluable insights into drug efficacy and resistance. This new service is a direct step towards personalizing oncology and accelerating the path to market for groundbreaking therapies.”
In the future, the collaboration holds potential for expansion into secondary treatment and combination studies, aiming to further address drug resistance and optimize therapeutic strategies.
Seeking Partnership to Advance Oncology Drug Development
Both Inoviem Scientific and abc biopply are actively seeking partnerships with pharmaceutical and biotech innovators to leverage this novel preclinical service. The goal is to work with companies on a collaborative basis to apply this platform for early-stage drug evaluation, helping to accelerate decision-making, reduce attrition, and ultimately bring more effective therapies to patients. We invite interested parties to learn more about how this unique, patient-relevant platform can improve the translational accuracy of their oncology drug development pipelines
About abc biopply: abc biopply’s integrated preclinical project services guarantee you the support of your drug discovery projects by a single, efficient integrated team from early stage to clinical and from in vitro to in vivo from a single source. Our expert scientific guidance helps you to tailor studies to your specific needs. Our full range of proprietary in vitro, ex vivo and in vivo assays and models streamline your development time to the clinic and makes sure that your funds and resources are used optimally. The company is renowned for its proprietary 3D CoSeedis humanized multi-organoid in chip models™, which are transforming preclinical research by creating precise physiological microenvironments.
About Inoviem Scientific: Inoviem Scientific is a pioneering Bioanalytical R&D company established in Strasbourg, France, in 2011. The firm specializes in translational pharmacology, focusing on accelerating and de-risking the drug development process from bench to bedside and back again. Its mission is precise: to ensure the right treatment reaches the right patient at the right therapeutic window. The expert team collaborates closely with big pharma, biotech, and research institutions across the globe to deliver critical insights in Target Identification and Deconvolution, Clinical Mechanism of Action (MoA) Elucidation, and Biomarker Discovery and Patient Stratification. With expertise in challenging targets like GPCRs and membrane proteins, Inoviem Scientific has successfully contributed to over 200 discovery, preclinical, and clinical studies. The company’s experience spans nearly all major therapeutic areas, including Oncology, Autoimmune, Inflammatory, Fibrosis, Respiratory, Metabolic, Neurodegeneration, and CNS-related disorders.
Contacts:
For Inoviem Scientific:
www.inoviem.com
a.bona@inoviem.com
